Intellia Therapeutics announced positive results from a late-stage trial of its Crispr-based treatment for hereditary angioedema, a rare condition causing severe swelling. The treatment, which modifies DNA to inhibit the overproduction of a harmful peptide, achieved an 87% reduction in swelling attacks compared to placebo. With 62% of patients free from attacks six months post-treatment, Intellia is poised to seek FDA approval, aiming for a U.S. launch in the first half of next year.

This development is significant for the gene editing landscape, particularly as it marks the first Phase 3 data demonstrating in vivo Crispr therapy’s potential to permanently alter disease-causing genes. While Intellia’s treatment could disrupt the market for chronic HAE medications, it must navigate the challenges faced by previous gene therapies, such as commercial viability and long-term efficacy.

For market professionals, Intellia’s progress underscores the growing promise of in vivo gene editing, potentially reshaping treatment paradigms in rare diseases and offering insights into future investment opportunities in the biotech sector.

Source: cnbc.com